FH and metabolic dysfunction-associated steatotic liver disease: Itaconate is known to modulate the immune and antioxidant responses [58], and miR-144, by preventing itaconate synthesis, increases FH activity, potentially contributing to non-alcoholic fatty liver disease [57, 59, 60].